Owlstone Medical's cancer detecting breathalyser crowned 'Invention of the Year'

Posted on 12 December 2016 (Permalink)

Owlstone Medical, an SBRI Healthcare-backed company developing a breathalyser for early detection of disease, has had its ReCIVA Breath Sampler named 'Invention of the Year' in the 2017 Top 50 in Digital Health Awards.

SBRI Healthcare is an NHS England initiative, led by the Academic Health Science Networks (AHSNs). Winners receive fully funded development contracts between the awarded company and NHS England to meet known healthcare need.

The breath sampler is used with Owlstone Medical's sensor platform to accurately analyse and detect biomarkers of disease in a person’s breath. The technology diagnoses cancer development earlier than current tests.

Owlstone Medical uses the Respiration Collector for In Vitro Analysis (ReCIVA), in combination with Field Asymmetric Ion Mobility Spectrometer (FAIMS) sensor platform, to accurately and sensitively detect targeted biomarkers of disease in breath.

Karen Livingstone, National Director for SBRI Healthcare and Director at Eastern AHSN, said: “We are delighted that Owlstone Medical has been awarded Invention of the Year at the prestigious Top 50 in Digital Health Awards. Early detection of cancer saves lives, so we need to find quick, non-invasive, and cost-effective ways to screen people. SBRI Healthcare, an AHSN led initiative, supports the development of cutting-edge solutions. We recognise that the development of new healthcare technologies can be challenging - so it is great to be part of this excellent success story.”